A recent meta-analysis published in the British Journal of Sports Medicine pooled data from 21 randomized controlled trials including 8,449 participants and found that structured exercise after cancer treatment was associated with improved outcomes. In the pooled analysis, participants assigned to structured exercise programs had a 17% lower risk of cancer recurrence and a 26% lower risk of dying from cancer compared with control groups. The analysis reported improvements in overall survival, disease-free survival, and reductions in both all-cause and cancer-specific mortality.
The trials included a range of tumor types, with the most frequently studied cancers being breast cancer, colorectal cancer, and pancreatic cancer. The article highlights that the observed benefits were more apparent in studies of people with earlier-stage disease and in trials that implemented aerobic exercise interventions.
The source article summarizes the pooled results: a 17% relative reduction in recurrence risk and a 26% relative reduction in cancer-specific mortality for participants following structured exercise regimens. These conclusions derive from the combined data across 21 randomized controlled trials and 8,449 participants; further trial-level details, such as individual trial sizes, intervention durations, or specific statistical methods, were reported in the original meta-analysis but are not reproduced in full in the source article.
Adherence emerged as an important factor: studies reporting high adherence (approximately 70% or higher) showed greater participant benefit. The article also notes that trials enrolling people with earlier-stage cancers tended to show clearer benefit, while trials in more advanced-stage populations often had smaller sample sizes, which may affect subgroup interpretations.
The meta-analysis differentiated outcomes by exercise modality. Aerobic exercise alone was associated with the strongest reduction in relative risk of death (reported as about 29% lower relative risk). Combined aerobic plus resistance training also showed benefit (around a 25% lower relative risk of death). By contrast, resistance training alone did not demonstrate a statistically significant survival benefit in the pooled analysis.
These modality-specific findings suggest that aerobic components may drive much of the observed survival advantage in the available randomized trials, though combined programs also conferred meaningful reductions in mortality in the pooled data.
The article includes expert perspectives to contextualize the findings. Diana Garrett, PT, DPT, noted that exercise is a systemic intervention affecting multiple organ systems, including the cardiovascular system and the immune system, and can lead to physiologic adaptations such as increased cardiac output and more efficient cardiac function. She also highlighted prior evidence that regular physical activity can increase immune activity, which may be relevant for people with a history of cancer.
Mike Lattanzi, MD, commented that exercise induces widespread cellular and tissue changes and cited hypotheses that physical activity might impair cancer cell metabolism and enhance antitumor immune-cell efficacy. The article presents these as plausible mechanisms rather than new trial outcomes.
The American Cancer Society and the experts quoted in the article emphasize that exercise is generally safe for most people before, during, and after cancer treatment, but safety must be individualized. Key factors to consider when recommending or prescribing exercise include:
The article notes that some chemotherapy agents can adversely affect the cardiovascular system, which may require modification of exercise intensity or supervised activity in a controlled environment. For frail or elderly patients, musculoskeletal injury risk and potential loss of mobility are important considerations that could negatively affect outcomes if not addressed in the exercise plan.
The article advises that people undergoing or having completed cancer treatment should discuss physical activity plans with their oncology team. Experts recommend coordinating activity with the multidisciplinary care team — for example, consulting oncologists, primary care physicians, cardiologists, and physical therapists — to define safe target heart rates and identify necessary exercise modifications.
A baseline assessment of cardiovascular fitness and strength is recommended to inform individualized program design. Physical therapists may use those baseline measures to set progressive targets and to tailor intensity, duration, and modality (aerobic, resistance, or combined) based on tolerance, treatment history, and goals.
Although the meta-analysis suggests that aerobic exercise, alone or combined with resistance training, was associated with the most consistent survival benefit, the article underscores that exercise prescriptions should be individualized. Clinicians should consider the patient’s cancer stage, current health status, prior treatments, and functional capacity when recommending a structured exercise plan.
Note: The summary above reflects findings and expert commentary as presented in the source article. Detailed trial-level data, protocol specifics, and statistical methods from the original meta-analysis are not reproduced in full in the source article and would need to be consulted in the published British Journal of Sports Medicine paper for complete methodological information.